Lancet Infectious Diseases最新文献

{"title":"The (Re)-emerging And ePidemic Infectious Diseases (RAPID) Stigma Scales: a cross-outbreak scale development and pyschometric validation study","authors":"Amy Paterson, Kondwani K Mughogho, Ashleigh Cheyne, Olive Kabajaasi, Tonmoy Sarkar, Kkunsa Hadson Dimitrios, Harun Tulunay, Frances N Adiukwu, Saad S Alatrany, Ebrahim Aliafsari Mamaghani, Lorena G Barberia, He Bu, Precious Chikura-Dlamini, Jake Dunning, Ernesto R Gregorio, Md Zakiul Hassan, Mohammad B Hossain, Euzebiusz Jamrozik, Sabuj Kanti Mistry, Gerald A Mwima, Amanda Rojek","doi":"10.1016/s1473-3099(25)00161-6","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00161-6","url":null,"abstract":"Reducing stigma during infectious disease outbreaks is crucial for delivering an effective response. However, no validated stigma scales exist for use across outbreaks, and outbreak-specific scales are developed too slowly to guide timely interventions. To enable more real-time monitoring and mitigation of stigma across outbreak contexts, we developed and validated the (Re)-emerging and ePidemic Infectious Diseases (RAPID) Stigma Scales. Field testing and psychometric validation were conducted in communities affected by Ebola disease in Uganda, mpox in the UK, and Nipah virus disease in Bangladesh. Content validity was established through cognitive interviews and expert Delphi scoring. 1008 respondents were included across the three countries. The final RAPID Community Stigma Scale (12 items) captures initial social stigma, provider or authority-related stigma, structural stigma, and enduring social stigma. The RAPID Self Stigma Scale (4 items) is unidimensional. Both scales were found to have robust psychometric properties, including content validity, structural validity (factor loadings ≥0·6), and reliability (ordinal alphas 0·79–0·92). High scores on both scales predicted an increased hesitancy to report symptoms and seek care. The RAPID Stigma Scales are validated tools for real-time assessment of stigma across outbreak settings, enabling responders to design targeted interventions to improve health outcomes and promote equitable care.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"71 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144183847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 mortality in Africa and Asia – Authors' reply","authors":"Philip Bejon, Ambrose Agweyu, Isabella Oyier, Mainga Hamaluba, Dorcas Kamuya, Sam Kinyanjui, Edwine Barasa","doi":"10.1016/s1473-3099(25)00350-0","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00350-0","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"36 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 mortality in Africa and Asia","authors":"Sandro Vento","doi":"10.1016/s1473-3099(25)00348-2","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00348-2","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"45 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144177003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Infect Dis; published online May 19. https://doi.org/10.1016/S1473-3099(25)00341-X","authors":"","doi":"10.1016/s1473-3099(25)00360-3","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00360-3","url":null,"abstract":"<em>Có ACG, de Mendonça GC, Gatti FD, et al. Unravelling the pathogenesis of Oropouche virus.</em> Lancet Infect Dis <em>2025; published online May 19. https://doi.org/10.1016/S1473-3099(25)00341-X</em>—In this Correspondence, Joaquim Batista Ferreira Filho should have been included as an author. This correction has been made to the online version as of May 29, 2025, and will be made to the printed version.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"26 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is shorter the solution for tuberculosis treatment?","authors":"Rosa Herrera, Jennifer Furin","doi":"10.1016/s1473-3099(25)00163-x","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00163-x","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"26 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144122616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial","authors":"Nicholas I Paton, Christopher Cousins, Intan P Sari, Erlina Burhan, Nan-Kai Ng, Victoria B Dalay, Celina Suresh, Tutik Kusmiati, Ka Lip Chew, Vincent M Balanag, Qingshu Lu, Rovina Ruslami, Irawaty Djaharuddin, Jani J R Sugiri, Rholine S Veto, Christine Sekaggya-Wiltshire, Anchalee Avihingsanon, Jitendra Kumar Saini, Padmasayee Papineni, Andrew J Nunn, Reinout Van Crevel","doi":"10.1016/s1473-3099(25)00151-3","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00151-3","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;WHO recommends a 2-month optimal duration for new drug regimens for rifampicin-susceptible tuberculosis. We aimed to investigate the efficacy and safety of the 8-week regimens that were assessed as part of the TRUNCATE management strategy of the TRUNCATE-TB trial.&lt;h3&gt;Methods&lt;/h3&gt;TRUNCATE-TB was a multi-arm, multi-stage, open-label, randomised controlled trial in which participants aged 18–65 years with rifampicin-susceptible pulmonary tuberculosis were randomly assigned via a web-based system, using permuted blocks, to 24-week standard treatment (rifampicin, isoniazid, pyrazinamide, and ethambutol) or the TRUNCATE management strategy comprising initial 8-week treatment, then post-treatment monitoring and re-treatment where needed. The four 8-week regimens comprised five drugs, modified from standard treatment: high-dose rifampicin and linezolid, or high-dose rifampicin and clofazimine, or bedaquiline and linezolid, all given with isoniazid, pyrazinamide, and ethambutol; and rifapentine, linezolid, and levofloxacin, given with isoniazid and pyrazinamide. Here, we report the efficacy (proportion with unfavourable outcome; and difference from standard treatment, assessed via Bayesian methods) and safety of the 8-week regimens, assessed in the intention-to-treat population. This prespecified exploratory analysis is distinct from the previously reported 96-week outcome of the strategy in which the regimens were deployed. This trial is registered with &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt; (&lt;span&gt;&lt;span&gt;NCT03474198&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;).&lt;h3&gt;Findings&lt;/h3&gt;Between March 21, 2018, and March 26, 2020, 675 participants (674 in the intention-to-treat population) were enrolled and randomly assigned to the standard treatment group or one of the four 8-week regimen groups. Two 8-week regimens progressed to full enrolment. An unfavourable outcome (mainly relapse) occurred in seven (4%) of 181 participants on standard treatment; 46 (25%) of 184 on the high-dose rifampicin and linezolid-containing regimen (adjusted difference 21·0%, 95% Bayesian credible interval [BCI] 14·3–28·1); and 26 (14%) of 189 on the bedaquiline and linezolid-containing regimen (adjusted difference 9·3% [4·3–14·9]). Grade 3–4 adverse events occurred in 24 (14%) of 181 participants on standard treatment, 20 (11%) of 184 on the rifampicin-linezolid regimen, and 22 (12%) of 189 on the bedaquiline-linezolid regimen.&lt;h3&gt;Interpretation&lt;/h3&gt;Efficacy was worse with 8-week regimens, although the difference from standard treatment varied between regimens. Even the best 8-week regimen (bedaquiline","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"45 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144122685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19: the challenges of a digital pandemic | Risk and crisis communication during the COVID-19 pandemic: muddled messages, Martin Ndlela (Ed.), Routledge (2024), p. 200, £39·99, ISBN: 9781032513577","authors":"Henrietta Dunsmuir","doi":"10.1016/s1473-3099(25)00353-6","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00353-6","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"130 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144122615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study","authors":"Pedro M Folegatti, Stephanie Pepin, Cynthia Tabar, Katherine Fries, Oxana Talanova, Stephanie See, Brandon Essink, Todd Bertoch, Daniel Drazan, Silvina Natalini Martínez, Marek Konieczny, Kathleen Kaas-Leach, Iris De Bruijn","doi":"10.1016/s1473-3099(25)00153-7","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00153-7","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;The recombinant influenza vaccine (RIV) is licensed for adults older than 18 years but is not approved for paediatric groups. This study aimed to demonstrate the non-inferior immune responses and safety of RIV in participants aged 9–17 years compared with adults aged 18–49 years.&lt;h3&gt;Methods&lt;/h3&gt;This was a phase 3, non-randomised, immunobridging, open-label, uncontrolled study conducted at 36 centres in Europe and the USA during the 2022–23 northern hemisphere influenza season. The main exclusion criteria were receipt of an influenza vaccine up to 6 months before enrolment and receipt of any other vaccines within 4 weeks before or after study intervention (except for COVID-19 vaccination, which was allowed at least 2 weeks before or after enrolment). Healthy participants aged 9–49 years received a single dose of quadrivalent RIV and were followed up for 6 months on days 9, 29, and 181. Haemagglutination inhibition (HAI) assays to assess immunogenicity were used to test blood samples obtained at baseline and day 29. The primary outcome was the non-inferiority of immune response at day 29 as assessed by HAI titre ratios and differences in seroconversion rates between the two age groups. The non-inferiority of a geometric mean titre was demonstrated if the lower limit of the two-sided 95% CI of the geometric mean titre (GMT) ratio was above 0·667 for each of the four strains of virus. Similarly, the non-inferiority of seroconversion was demonstrated if the lower limit of the two-sided 95% CI was −10% or above for each of four strains. Safety was monitored throughout the study. This study was registered at &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt; (&lt;span&gt;&lt;span&gt;NCT05513053&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;) and is complete.&lt;h3&gt;Findings&lt;/h3&gt;Between Oct 27, 2022, and May 1, 2023, a total of 1308 participants were enrolled, all of whom attended the first study visit. 1299 participants (99%) received the study vaccine (641 participants [49%] in the age 9−17 years group and 658 participants [51%] in the age 18−49 years group). The mean age of participants in the age 9−17 years group was 13·0 years (SD 2·5) and was 34·3 years (9·2) in the age 18−49 years group. Overall, 707 participants (54%) were female and 601 participants (46%) were male. Most of the participants were White (1003 [77%] of 1308); the next largest category was Black or African American (255 [19%]); 149 (11%) participants identified as Hispanic or Latino. The HAI GMT ratio between the paediatric and adult groups at day 29 in the per-protocol analysis set was 2·0 (95% CI 1·7 to 2·3), 3·3 (2·8 to 3·9), ","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"8 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144114336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Infect Dis 2025; 25: 690–700","authors":"","doi":"10.1016/s1473-3099(25)00303-2","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00303-2","url":null,"abstract":"<em>Sigfrid L, Chan XHS, Kasbergen LMR, et al. Prevalence, clinical management, and outcomes of adults hospitalised with endemic arbovirus illness in southeast Europe (MERMAIDS-ARBO): a prospective observational study.</em> Lancet Infect Dis <em>2025; published online Feb 20. https://doi.org/10.1016/S1473-3099(24)00655-8</em>—In this Article, corrections have been made to the data in figure 3. These corrections have been made to the online version as of May 21, 2025 and the printed version is correct.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"45 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144114341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infectious disease surveillance update","authors":"Cahal McQuillan","doi":"10.1016/s1473-3099(25)00301-9","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00301-9","url":null,"abstract":"&lt;h2&gt;Section snippets&lt;/h2&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Yellow fever in Peru&lt;/h2&gt;As of April 24, 2025, 32 cases of yellow fever, including 11 deaths, have been confirmed in &lt;span&gt;&lt;span&gt;Peru&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;. All infections were in individuals with a history of exposure to wild or wooded areas due to hunting or agricultural work. 23 (72%) infections were in individuals with no history of vaccination against yellow fever. The Peruvian Ministry of Health announced they will intensify response actions, epidemiological surveillance, and vaccination against yellow fever in response to the epidemic.&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Measles in Canada&lt;/h2&gt;As of April 12, 2025, 1069 confirmed measles cases have been reported in seven provinces in &lt;span&gt;&lt;span&gt;Canada&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;, compared with just 177 confirmed and probable cases reported in 2024. The majority (83%) of cases this year are linked to a large, multi-jurisdictional outbreak occurring among unvaccinated individuals in undervaccinated communities. 1008 (94%) infections are in unvaccinated individuals or those with unknown vaccination status. Public health officials are urging people to get vaccinated,&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Polio in Nigeria&lt;/h2&gt;Between Jan 1 and April 23, 2025, 14 cases of circulating vaccine-derived poliovirus type 2 (cVDPV2) were reported in &lt;span&gt;&lt;span&gt;Nigeria&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;. Three cVDPV2 cases, with onsets of paralysis in March, were reported in Sokoto and Yobe during April 21–23. Additionally, two cases were reported in Jigawa after nearly a decade of being polio-free. In response to the epidemic, Nigeria is intensifying efforts to halt transmission, and there have been renewed calls to strengthen routine immunisation efforts and&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Chikungunya in Réunion&lt;/h2&gt;According to the French National Health Authority, more than 44 000 confirmed autochthonous cases of chikungunya virus disease were reported in &lt;span&gt;&lt;span&gt;Réunion&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt; between Jan 1 and April 27, 2025. During April 14–20, 3245 new cases were confirmed—a decrease from a weekly high of 6289 infections during March 24–30. This decrease is likely linked to the cessation of systematic l","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"57 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144114349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}